Objective. This study aims to analyze the expressions of miR-21, miR-29, and miR-199 in the serum of the patients with H-type hypertension among Kazakhs. Then, we analyzed the effect of MTHFR 677C>T polymorphism on the association between the above miRNA and H-type hypertension. Method. In this study, the expression of miR-21, miR-29, and miR-199 was quantitatively measured in 120 serum samples and then stratified according to the C677T polymorphism to analyze the relationship between target miRNAs and HHcy. Results. The expression of miR-21/29 in the hypertension group was higher than the normal group (P < 0.001). And the expression of miR-199 was higher in the hcy group than in the normal group (P < 0.001). In the CC and CT genotypes of MTHFR 677C>T, the expression of miR-21 was lower in the HHcy patients than in the normal individuals (P = 0.005 and P = 0.001) and miR-199 was significantly higher in the HHcy patients than in the normal ones (P = 0.002 and P = 0.048). No such difference was found in the TT genotype. Logistic regression analysis showed that after adjusting for sex, age, BMI, systolic blood pressure, diastolic blood pressure, and MTHFR677 T gene polymorphism, miR-21 was negatively correlated with hcy (OR = 0.222, 95% CI (0.101–0.485), P < 0.001) and miR-199 was positively correlated with hcy (OR = 1.823, 95% CI (1.272–2.614), P = 0.001). Conclusion. miR-21, miR-29, and miR-199 are associated with H-type hypertension in the Kazakhs, especially hyperhomocysteinemia. And these three miRNAs may serve as biomarkers to provide clues to the potential pathogenesis of H-type hypertension.

1. Introduction

Homocysteine (hcy) is an intermediate product of methionine metabolism, and pathological accumulation causes homocysteinemia (HHcy, hcy ≥15 umol/l) [1]. Studies have shown that HHcy and hypertension are synergistic factors that increase the risk of cardiovascular disease [2]. In China, 75% of people with hypertension have hyperhomocysteinemia (defined as H-type hypertension) [3], but the pathogenesis is unclear. There is growing evidence that genetic factors are involved in the biology of H-type hypertension.

MicroRNAs (miRNAs) are a class of small noncoding RNAs about 22 nucleotides long. By binding to the 3′-untranslated region (3′-UTR) of mRNAs, miRNAs degrade miRNAs and inhibit the translation of target genes and subsequent silencing gene expression, which is the main mode of action of miRNAs. It has received much attention as a stable and specifically expressed marker in cardiovascular diseases, including hypertension [4]. Indeed, there is growing evidence that miR-21, miR-29b, and miR-199a are involved in biological processes associated with H-type hypertension. Located on chromosome 17q23.2 [5], miR-21 has long been valued for its role in tumor, cardiovascular, and lung diseases. MiR-21 acts like a proto-oncogene and promotes malignancy progression by participating in processes such as regulation of the cell cycle and gene expression and has a key role in angiogenesis, apoptosis,
and cardiac and renal fibrosis [6]. MiR-21 has been shown to be a key molecule in the regulation of vascular remodeling during essential hypertension [7]. Clinical and experimental studies have demonstrated that miR-21 expression levels are positively correlated with hypertension [8]. The miR-29 family has three members (miR-29a, miR-29b, and miR-29c), and studies have shown that miR-29b plays an important role in cardiac fibrosis (by inhibiting extracellular matrix production), lipid homeostasis, endothelial function (by increasing NO production), left ventricular remodeling, T2DM management, and a variety of cancers [6]. And miR-29b expression levels are positively correlated with 24 h mean blood pressure, daytime mean blood pressure, office blood pressure, and LVMI (left ventricular mass index) [9]. MiR-199a is a new miRNA molecule with multiple biological functions discovered in serum and other tissues in animals in recent years, which plays a key role in the growth and development of many organisms, as well as in the pathophysiology of some diseases, and is particularly closely associated with various tumors, vascular injury, cell proliferation, and regulation. Basic and clinical studies at home and abroad have confirmed that miR-199a is mainly expressed in cardiomyocytes, its expression level is abnormal in a variety of cardiovascular diseases, and its overexpression induces cardiomyocyte-specific miR-199a transgenic mice with cardiac hypertrophy and heart failure [10]. Lynch et al. [11] found a significant negative correlation between miR-199a-5p and SMAD4 (recombinant mothers against decapentaplegic homolog 4, which has been previously implicated in hypertension) expression, with miR-199a-5p affecting blood pressure by targeting SMAD4. This study also confirmed that serum miR-199a-5p expression in the patients with methylenetetrahydrofolate reductase (MTHFR) 677TT genotype was somehow associated with hypertension in individuals in the TT group. Subsequently, 30 subjects were randomly selected from each group for microRNA measurement. Hyperhomocysteinemia was defined as plasma hcy ≥15 μmol/L; according to the Chinese Guidelines of hypertension management in 2018 [3], those with systolic blood pressure ≥140 mm-Hg and/or diastolic blood pressure ≥90 mm-Hg; those with a clear previous history of hypertension and diagnosed at a hospital at the county level or above; or those who have taken hypertensive medication in recent 2 weeks were judged to be hypertension.

2. Methods

2.1. Subjects and Sample Collection. Subjects came from the Kazakh cohort of Xinyuan County from 2009 to 2017. The subjects were divided into 4 groups based on serum hcy levels and blood pressure levels: H-type hypertension group (HT+Hcy, hypertension accompanied by hyperhomocysteinemia), simple hypertension group (HT, hypertension and no hyperhomocysteinemia), simple hyperhomocysteinemia group (Hcy, hyperhomocysteinemia and no hypertension), and normal control group (CONTROL, no hypertension and no hyperhomocysteinemia), with a sample size of 100 subjects in each group. Subsequently, 30 subjects were randomly selected from each group for miRNA measurement. Hyperhomocysteinemia was defined as plasma hcy ≥15 μmol/L; according to the Chinese Guidelines of hypertension management in 2018 [3], those with systolic blood pressure ≥140 mm-Hg and/or diastolic blood pressure ≥90 mm-Hg; those with a clear previous history of hypertension and diagnosed at a hospital at the county level or above; or those who have taken hypertensive medication in recent 2 weeks were judged to be hypertension.

2.2. Blood Biochemistry. 5 ml of whole blood was collected from the subject’s fasting morning blood with sodium heparin anticoagulation, centrifuged to separate the plasma, numbered, and stored in the refrigerator at −80°C for testing the biochemical indexes.

2.3. Genotyping. DNA was extracted in the subject's serum samples using the kit (TIANamp Genomic DNA Kit) and typing of the MTHFR rs1801133 single nucleotide polymorphism was completed using an ABI13730XL sequencer.

2.4. Selection of miRNA. The miRNAs were selected by the following inclusion criteria in our study.

All miRNAs are expressed in plasma although they are not unique; they all have a wide distribution on chromosomes.

They have not been studied in H hypertension: miR-21 and miR-29 have been studied in patients with hypertension but not yet in patients with H hypertension; miR-199a is expressed in cardiomyocytes but its changes have not been detected in the plasma of patients with H hypertension; the miRNAs used in the study have a relevant role in different physiological processes of H hypertension as well as in pathogenic processes.

2.5. miRNA Analysis. Total RNA was extracted from serum using the Trizol method. Next, 20 μl of cDNA was synthesized by reverse transcription using the Thermo-fermented reverse transcription polymerase reaction kit. 20 μl of PCR reaction system was configured according to the instructions of QIAGEN’s QuantiNova SYBR Green Dye Method PCR kit, followed by 2-3 wells of quantitative PCR reactions using a fluorescent quantitative U6 snRNA which
was used as an internal reference. MiRNA-21 sequence was 5'-TCAGCCAACACCAGTCGATGGTGGCAAGGTCCGA GGT-3'; the miR-29b sequence is 5'-ACAGCAATTAG CACCATTTGATATGGCCTCTTCTCTGTCGTC-3'; the miR-199a sequence is 5'-CCGAGACCCAG TGTCAGACTACCATGGGTGTCGTCGAGT-3'; the U6 sequence is 5'-CAGCACATATACTAAATTGG AAGCAGCAATTTGTCGTCAATCC-3'. The above miRNA and U6 sequences were designed and synthesized by Shanghai GenePharma Co., Ltd. The expression of the above miRNAs was determined under the following conditions: 95°C for 2 minutes, followed by 45 cycles of 95°C for 30 seconds and 60°C for 20 seconds. The data were analyzed using quantitative rotor gene software. The relative expression levels of miR-21, miR-29b, and miR-199a were calculated using the 2^-ΔΔCT method.

2.6. Statistical Analysis. All data were tested for normality (Kolmogorov–Smirnov). Continuous variables were described by X ± SD, categorical variables were described by frequencies and percentages. For normally distributed data, one-way analysis of variance (ANOVA) was used for comparisons of multiple groups (≥ 3), and the LSD test was used for two-by-two comparisons. The Kruskal–Wallis test was used for comparison of non-normally distributed data. Statistical data were compared using χ^2 test. Pearson correlation was used to explore the relationship between miRNA and hcy, systolic blood pressure, and diastolic blood pressure. Logistic regression was used to analyze the relationship between target miRNA and hcy.

3. Result

3.1. Baseline Characteristics of Patients with Type H Hypertension. The baseline characteristics of participants in four groups are shown in Table 1. There were differences in gender distribution, age, BMI, and smoking between the four groups (P < 0.05). And there were statistically significant differences in hcy, systolic blood pressure, and diastolic blood pressure between the groups. Among them, there were statistically significant differences between the H-type hypertension group and the control group in age, hcy level, mean systolic blood pressure, and mean diastolic blood pressure; between the simple hypertension group and the normal control group in age, BMI, mean systolic blood pressure, and mean diastolic blood pressure; and between the simple hyperhomocysteinemia group and the normal control group in hcy level and mean systolic blood pressure (P < 0.05).

3.2. Expression Levels of miR-21, miR-29, and miR-199 among the Four Groups. As shown in Table 2, there were significant differences in the expression levels of miR-21, miR-29, and miR-199 among the four groups. As shown in Figure 1(a), the expression of miR-21 was significantly higher in the HT group than in the other three groups (P < 0.001).

Furthermore, the difference was statistically significant in the HCY group compared with the CONTROL group (P < 0.001), and the expression of miR-21 was lower in the HCY group than in the CONTROL group (0.32 ± 0.29, 0.88 ± 0.66, P = 0.022). MiR-29 was expressed higher in the HT group than in the other three groups (P < 0.001), and the expression level of miR-29 was higher in the HT + HCY Deleted group compared with the CONTROL group (1.91 ± 1.54, 0.34 ± 0.24, P = 0.027) (Figure 1(b)). The expression of miR-199 was higher in the patients with pure hyperhomocysteinemia than in the other three groups, and there was a significant difference (P < 0.001) (Figure 1(c)).

3.3. Baseline Characteristics among MTHFRC677T Genotypes. As shown in Table 3, the differences in systolic and diastolic blood pressure between the genotypes of MTHFRC677T were statistically significant. There were no differences in sex, age, BMI, and hcy.

3.4. Association of MTHFRC677T Gene Polymorphism with Serum miR-199, miR-29, and miR-21 Expression. The HHcy patients with different genotypes of MTHFR (CC, CT, TT) were grouped according to each genotype, and the mRNA expression as well as the changes in blood pressure and hcy in each genotype was analyzed (Table 4). As shown in Table 2, in the CC genotype, there were statistically significant differences in the expression of hcy levels, miR-21, and miR-199 in the HHcy patients and the normal individuals. Moreover, the expression of miR-21 was lower in the HHcy patients than in the normal patients (0.29 ± 0.25 vs. 0.99 ± 1.23, P = 0.005), while the HHcy patients had higher miR-199 expression levels than the healthy individuals (3.35 ± 2.83 vs. 0.89 ± 1.61, P = 0.002). The expression of miR-21 was lower in the HHcy patients than in the normal individuals in the CT genotype (0.43 ± 0.53 vs. 1.44 ± 1.16, P = 0.001), and miR-199 expression was higher in the HHcy patients than in the normal individuals (1.84 ± 1.82 vs. 0.92 ± 1.00, P = 0.048) while no such differences were found in the TT genotype.

3.5. Association of Serum miR-199, miR-29, miR-21, and MTHFRC677T Gene Polymorphisms with H-type Hypertension. Correlation analysis showed that miR-21 was negatively correlated with hcy. miR-29 was positively correlated with systolic and diastolic blood pressure. miR-199 was positively correlated with hcy and negatively correlated with systolic and diastolic blood pressure (Table 5). Logistic regression analysis (Figure 2) showed that after adjusting for gender, age, BMI, systolic blood pressure, diastolic blood pressure and MTHFRC677T gene polymorphism, miR-21 expression level was significantly and negatively correlated with hyperhomocysteinemia prevalence (OR = 0.222, 95% CI: (0.101–0.485), P < 0.001), and each unit increase in miR-199 expression was associated with an increased risk of hyperhomocysteinemia (OR = 1.823, 95%CI: (1.272–2.614), P = 0.001). And the miR-29 did not correlate with HHcy (P = 0.063) shown in Figure 2(b).
Table 1: Baseline characteristics of the four groups.

|                      | HT + hcy (n = 100) | HT (n = 100) | hcy (n = 100) | NC (n = 100) | F/χ² | P     |
|----------------------|--------------------|--------------|--------------|--------------|------|-------|
| Gender               |                    |              |              |              |      |       |
| Male                 | 61                 | 39           | 59           | 52           |      | 11.906| 0.008*|
| Female               | 39                 | 61           | 41           | 48           |      |       |
| Age (years)          | 53.54 ± 13.52a     | 49.40 ± 10.27a| 42.09 ± 12.31| 41.86 ± 10.10| 24.308| <0.001*|
| BMI (Kg/m²)          | 25.76 ± 5.03       | 26.56 ± 4.25a| 24.55 ± 3.35| 24.91 ± 4.27| 4.543 | 0.004*|
| Smoking              |                    |              |              |              |      |       |
| No                   | 60                 | 83           | 63           | 73           | 15.486| 0.001*|
| Yes                  | 40                 | 17           | 37           | 27           |      |       |
| Family history of hypertension |            |              |              |              |      |       |
| No                   | 58                 | 47           | 57           | 54           | 2.979 | 0.395 |
| Yes                  | 42                 | 53           | 43           | 46           |      |       |
| HCY (umol/l)         | 22.69 ± 12.94a     | 12.18 ± 1.73  | 19.38 ± 6.46a| 11.01 ± 2.29  | 58.404| <0.001*|
| SBP (mm Hg)          | 160.64 ± 21.28a    | 158.36 ± 18.91a| 121.58 ± 9.74a| 126.91 ± 8.93a| 170.514| <0.001*|
| DBP (mm Hg)          | 94.50 ± 12.95a     | 92.59 ± 13.15a| 77.20 ± 6.89a| 76.37 ± 8.08a| 83.229| <0.001*|

*a P < 0.05 and ** P < 0.001 were considered significant; compared with normal control group. *P < 0.05.

Table 2: Comparison of the expression levels of miR-21, miR-29, and miR-199 in the four groups.

|                      | HT + hcy group (n = 30) | HT group (n = 30) | hcy group (n = 30) | NC group (n = 30) | P     |
|----------------------|-------------------------|-------------------|--------------------|-------------------|-------|
| MiR-21               | 0.42 ± 0.54             | 1.42 ± 1.48       | 0.32 ± 0.29        | 0.88 ± 0.66       | <0.001**|
| MiR-29               | 1.91 ± 1.54             | 3.30 ± 3.48       | 0.60 ± 0.82        | 0.34 ± 0.24       | <0.001**|
| MiR-199              | 1.52 ± 2.05             | 0.65 ± 1.50       | 3.51 ± 2.69        | 1.24 ± 1.06       | <0.001**|

*a P < 0.05 and ** P < 0.001 were considered significant.

Figure 1: Plots of the expression levels of miR-21, miR-29, and miR-199 in the four groups. The results of multiple comparisons of (a) miR-21, (b) miR-29, and (c) miR-199 in subjects in CONTROL, HT, hcy, and HT + hcy groups. Data are shown as X ± SD. *P values were generated by one-way ANOVA followed by LSD post hoc multiple comparison test. P < 0.05 or P < 0.001 was considered significant.

Table 3: Comparison of baseline characteristics among the four groups of MTHFR C677T genotypes.

|          | CC       | CT       | TT       | P     |
|----------|----------|----------|----------|-------|
| Sex      |          |          |          |       |
| Female   | 24       | 25       | 10       | 0.839 |
| Male     | 36       | 23       | 2        |       |
| Age (years) | 45.88 ± 12.81 | 47.82 ± 12.08 | 46.95 ± 13.51 | 0.357 |
| BMI (Kg/m²) | 25.29 ± 4.22  | 25.90 ± 4.45  | 24.66 ± 4.15  | 0.192 |
| SBP (mmHg) | 138.78 ± 21.80 | 145.72 ± 25.43 | 143.43 ± 24.42 | 0.021*|
| DBP (mmHg) | 83.47 ± 11.87 | 87.60 ± 15.28 | 84.85 ± 13.70 | 0.017*|
| HCY (μmol/l) | 15.63 ± 8.98   | 16.62 ± 9.05   | 18.62 ± 6.65   | 0.116 |

*a P < 0.05 and ** P < 0.001 were considered significant.
In the present study, MiR-21 was negatively correlated with serum hcy. However, few studies reported the association between MiR-21 and hcy. MiR-21 antagonists upregulated cystathionine-β-synthase (CBS) and cystathione-γ-cleavage enzyme (CSE) expression in an vitro assay [15]. CBS and CSE catalyze the removal of hcy through its conversion to cysteine. It has been suggested that CBS activity may be positively correlated with hcy levels. Therefore, our findings remain consistent with the above current theory [16, 17].

Correlation analysis showed that miR-29 was positively correlated with both systolic blood pressure and diastolic blood pressure. In multiple studies [9, 18], miR-29b has been shown to act as a biomarker of hypertension, but the relationship with hcy is unclear. HHCy has been shown to affect blood-brain barrier (BBB) integrity through upregulation of matrix metalloproteinases (MMPs) which plays a key role in tumor invasion and metastasis by degrading various protein components in the extracellular matrix (ECM) and destroying the histological barrier to tumor cell invasion, where BBB integrity is mediated by miR-29b through regulation of DNMT3B (DNA methyltransferases 3B) which regulates the levels of MMP9 (matrix metalloproteinases 9, which is the largest molecular weight enzyme in the matrix metalloproteinase family) [19]. The author also found that treatment with homocysteine (50–200 μM) increased miR-29b levels as well as MMP9 expression and activity in mouse brain endothelial cells. However, miR-29b was not shown to be correlated with hcy levels in this study, so the results may still be controversial. This may be due to different disease models.

We demonstrated that miR-199 expression levels were positively correlated with hcy and negatively correlated with hypertension. Previous studies reported miR-199a-5p as a circulating serum marker of hypertension [20, 21]. Upregulation of miR-199a-5p has been reported in the lung tissue from mouse and rat models of pulmonary artery hypertension (PAH), which also identified SMAD3 (which plays a key role in transmitting TGF-β signals from cell surface receptors to the nucleus) as a target gene of miR-199a-5p [10]. This link is important because defects in SMAD-dependent signaling have been linked to hypertension and cardiac pathologies, primarily through their association with TGF-β pathways [22]. This is not in line with the negative association of miR-199 with blood pressure in the present study. We speculate that the inconsistent results may be due to different disease types, different experimental models, different patient ethnicities, and different disease stages.

However, a retrospective human study found that the downregulation of miR-199a-5p in maternal peripheral blood was associated with gestational hypertension, preeclampsia, and intrauterine growth restriction. The authors also concluded that dysregulation of miR-199a-5p may be

### Table 4: Comparison of miRNA, blood pressure, and hcy levels of different genotypes of MTHFRC677T.

| CC   | MHcy (n = 28) | P   | CT   | MHcy (n = 23) | P   | TT   | MHcy (n = 9) | P   |
|------|--------------|-----|------|--------------|-----|------|--------------|-----|
| MiR-21 | 0.29 ± 0.25 | 0.005* | 0.43 ± 0.53 | 0.001** | 0.38 ± 0.50 | 0.001** | 0.62 ± 0.48 | 0.497 |
| MiR-29 | 1.03 ± 1.66 | 0.081 | 1.50 ± 0.95 | 0.500 | 1.59 ± 1.96 | 0.033 | 0.12 | 0.176 |
| MiR-199 | 3.35 ± 2.83 | 0.002* | 1.84 ± 1.82 | 0.048* | 2.31 ± 3.30 | 1.30 ± 0.43 | 0.691 |

SBP (mmHg) 143.08 ± 16.71 148.63 ± 26.11 141.80 ± 20.80 0.319 151.33 ± 33.93 132.67 ± 4.16 0.379

DBP (mmHg) 86.31 ± 10.68 87.09 ± 18.30 84.46 ± 15.14 0.589 84.00 ± 18.91 76.17 ± 8.61 0.513

Hcy (μmol/l) 23.71 ± 16.77 11.53 ± 1.98 0.001** 19.84 ± 7.17 11.10 ± 2.66 <0.001* 17.80 ± 3.34 10.80 ± 1.35 0.006* 15.14 ± 11.00 18.30 ± 17.60 143.08 ± 16.71 148.63 ± 26.11 141.80 ± 20.80 0.319 151.33 ± 33.93 132.67 ± 4.16 0.379 84.00 ± 18.91 76.17 ± 8.61 0.513 23.71 ± 16.77 11.53 ± 1.98 0.001** 19.84 ± 7.17 11.10 ± 2.66 <0.001* 17.80 ± 3.34 10.80 ± 1.35 0.006* 15.14 ± 11.00 18.30 ± 17.60 143.08 ± 16.71 148.63 ± 26.11 141.80 ± 20.80 0.319 151.33 ± 33.93 132.67 ± 4.16 0.379 84.00 ± 18.91 76.17 ± 8.61 0.513

*P < 0.05 and **P < 0.001 were considered significant.

### Table 5: Correlation of miR-21, miR-29, and miR-199 with hcy and blood pressure.

| Hcy | MiR-21 | MiR-29 | MiR-199 | SBP | DBP |
|-----|--------|--------|---------|-----|-----|
| -0.354** | 0.102 | 0.322** | 0.033 | 0.020 |
| -0.003 | 0.186 | -0.005 | 0.064 |
| -0.372** | 0.599** | 0.448** |
| -0.390** | -0.318** | 0.721** |

*P < 0.05 and **P < 0.001 were considered significant.

### 4. Discussion

The present study is the only one to demonstrate an association between miR-21, miR-29, and miR-199 and H-type hypertension, especially hyperhomocysteinemia in the Kazakh of Xinjiang, China. In this study, all subjects were come from the Kazakh cohort in Xinjiang and did not receive any intervention, and we had complete archived serum samples. We demonstrated the association of miR-21, miR-29, and miR-199 with H-type hypertension, considering whether the MTHFRC677T gene polymorphism affects miRNA expression and thus its association with H-type hypertension.

In the present study, MiR-21 was negatively correlated with serum hcy. However, few studies reported the association between MiR-21 and hcy. MiR-21 antagonists upregulated cystathionine-β-synthase (CBS) and cystathione-γ-cleavage enzyme (CSE) expression in an vitro assay [15]. CBS and CSE catalyze the removal of hcy through its conversion to cysteine. It has been suggested that CBS activity may be positively correlated with hcy levels. Therefore, our findings remain consistent with the above current theory [16, 17].

Correlation analysis showed that miR-29 was positively correlated with both systolic blood pressure and diastolic blood pressure. In multiple studies [9, 18], miR-29b has been shown to act as a biomarker of hypertension, but the relationship with hcy is unclear. HHCy has been shown to affect blood-brain barrier (BBB) integrity through upregulation of matrix metalloproteinases (MMPs) which plays a key role in tumor invasion and metastasis by degrading various protein components in the extracellular matrix (ECM) and destroying the histological barrier to tumor cell invasion, where BBB integrity is mediated by miR-29b through regulation of DNMT3B (DNA methyltransferases 3B) which regulates the levels of MMP9 (matrix metalloproteinases 9, which is the largest molecular weight enzyme in the matrix metalloproteinase family) [19]. The author also found that treatment with homocysteine (50–200 μM) increased miR-29b levels as well as MMP9 expression and activity in mouse brain endothelial cells. However, miR-29b was not shown to be correlated with hcy levels in this study, so the results may still be controversial. This may be due to different disease models.

We demonstrated that miR-199 expression levels were positively correlated with hcy and negatively correlated with hypertension. Previous studies reported miR-199a-5p as a circulating serum marker of hypertension [20, 21]. Upregulation of miR-199a-5p has been reported in the lung tissue from mouse and rat models of pulmonary artery hypertension (PAH), which also identified SMAD3 (which plays a key role in transmitting TGF-β signals from cell surface receptors to the nucleus) as a target gene of miR-199a-5p [10]. This link is important because defects in SMAD-dependent signaling have been linked to hypertension and cardiac pathologies, primarily through their association with TGF-β pathways [22]. This is not in line with the negative association of miR-199 with blood pressure in the present study. We speculate that the inconsistent results may be due to different disease types, different experimental models, different patient ethnicities, and different disease stages.

However, a retrospective human study found that the downregulation of miR-199a-5p in maternal peripheral blood was associated with gestational hypertension, preeclampsia, and intrauterine growth restriction. The authors also concluded that dysregulation of miR-199a-5p may be
associated with epigenetic alterations due to pregnancy-related complications [23]. This finding is relevant to our current study because MTHFR is a key enzyme in the Hcy metabolic pathway. Meanwhile, it may affect DNA methylation [20]. It has been shown that the methylated levels of NOS3 (nitric oxide synthase 3, which is mainly distributed in the endothelium of coronary vessels and cardiac luminal surfaces to catalyze the production of nitric oxide...
MTHFR 677TT genotype may be influenced by aberrant DNA regulated by its promoter methylation status [36]. The authors is evidence from COPD studies that miR-199a-5p is indeed in hypertension [34, 35]. In addition, it is noteworthy that there expression of DNA methylation-related genes have been re-group of patients [11]. Indeed, aberrant hypermethylation and miR-199a-5p with blood pressure was only evident in the TT and/or hcy levels [32]. It has been shown that the association of miR-21, miR-29, and miR-199 among patients with CC, CT, and TT genotypes in this study, miR-199a expression in patients with 677TT genotype may also be affected by aberrant DNA methylation in our sample due to the small sample size in this study. Therefore, different genotypes may affect the epigenetic mechanisms of miRNAs, especially DNA methylation, and thus their expression. If the epigenetic regulation of miR-21, miR-29, and miR-199 is similarly affected, then we deduced that different genotypes of MTHFR677TT may affect the miR-21, miR-29, and miR-199 association with hcy, but the exact mechanism is unknown to us.

Kazakhs have distinctive ethnic aggregation characteristics, living environment, and genetic background so they constitute extremely valuable genetic information. The prevalence of hypertension among Kazakhs was 36.5% in our group’s previous survey, which was significantly higher than that of local Han Chinese (28.9%) and Uyghurs (25.7%) [41]. Therefore, it is important to clarify the possible pathogenesis of H-type hypertension to prevent and treat hypertension in this ethnic group. In addition, it has been shown that ethnic differences may be a factor affecting miRNA expression. In the present study, miR-21 was significantly expressed in Kazakh hypertensive patients. In agreement with our results, Hu et al. showed that Han Chinese patients with pulmonary hypertension had higher circulating miR-21 levels than healthy controls. On the other hand, HHD patients had significantly lower miR-29 levels. However, miR-29 was positively correlated with SBP and DBP in our study, which is consistent with the findings of Luo et al. [9]. In addition, there are fewer studies on miR-199 expression in patients with H-type hypertension. It is noteworthy that the negative association of miR-199a-5p with blood pressure in patients with the MTHFR 677TT genotype found in the study of Lynch et al. is consistent with the results of our current study [11]. Whether the inconsistency of the above results is due to ethnic differences needs further validation.

4.1. Limitations. The conducted study incorporates several limitations. First, only a small sample was investigated in this study, so further confirmation in a larger prospective study at all stages of the disease is needed to clearly show that miR-21, miR-29, and miR-199 are true markers in patients with H-type hypertension. Second, there were fewer patients with MTHFR 677TT genotype in this study and more subjects should be recruited and similarly evaluated to further understand the relationship between the above-mentioned 3 miRNAs and MTHFR gene polymorphisms. Third, considering that there may be other microRNAs involved in H-type hypertension, a more comprehensive approach, such as microRNA arrays, may be needed to identify new targets.
other than miR-21/-29b/-199a. Last, the mechanism of miRNA action was not explored in this study, and the hypothesized potential mechanism is based on previous studies, and further experimental studies or raw letter analysis are needed to explore the unknown pathways of miR-21, miR-29, and miR-199 in H-type hypertension.

5. Conclusion

In summary, this study demonstrated that miR-21 was significantly negatively correlated with serum hcy levels, miR-199 expression levels were significantly positively correlated with serum hcy and negatively correlated with blood pressure, and correlation analysis showed that miR-29 was negatively correlated with both systolic and diastolic blood pressure, which has great clinical significance because local targeting of these miRNAs in patients with H-type hypertension may be a beneficial therapeutic strategy in the future. This study linked MTHFR C677T gene polymorphism with miRNA expression. Although miRNA expression did not differ between genotypes, gene polymorphisms are likely to disrupt the expression of transcription factors critical to miRNA transcription, indirectly affecting miRNA expression. MiR-21, miR-29b, and miR-199a could be used as biomarkers to provide clues to the underlying pathogenesis of H-type hypertension.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| HT           | Hypertension |
| HHcy         | Hyperhomocysteinemia |
| hcy          | Homocysteine |
| MTHFR        | Methylene-tetrahydrofolate reductase |
| miRNAs       | MicroRNAs |
| LVMI         | Left ventricular mass index |
| SMAD 4/3     | Recombinant mothers against decapentaplegic homolog 4/3 |
| CBS          | Cystathionine-β-synthase |
| CSE          | Cystathionine-γ-cleavage enzyme |
| BBB          | Blood-brain barrier |
| MMP          | Matrix metalloproteinase |
| DNMT 3B/3A/1 | DNA methyltransferase 3B/3A/1 |
| NOS3         | Nitric oxide synthase 3 |
| GNA12G       | Protein Subunit Alpha 12 |
| SAM          | S-Adenosylmethionine |
| P16          | Multiple tumor suppressor 1/MTS |
| PTEN         | Phosphate and tension homology deleted on chromosome ten |
| RASSF1A      | Ras association domain family 1A |
| TET 1/2      | Ten-eleven translocation 1/2 |

Data Availability

Data cannot be shared publicly. Datasets are available from the corresponding author by request.

Ethical Approval

The study was approved by the ethics review board of the First Affiliated Hospital of Shihezi University School of Medicine (IERB No. SHZ2010LL01), and all study subjects were informed of the study details and signed an informed consent form. All methods were carried out in accordance with relevant guidelines and regulations (declaration of Helsinki).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

The first author (Xin He) involved in experimental method design, laboratory experiments, data analysis, and writing the first draft of the paper. RuLin Ma, Yu Li, Wang, and YiZhong Yan led the sample data collection and were supervised by Shuxia Guo. ShengYu Liao, XueYing Sun, YiDan Mao, and Xin He participated in the laboratory experiments and were supervised by Heng Guo. Heng Guo supervised and directed the research project as well as the review and revision of the paper. All authors have read and approved the final manuscript.

Acknowledgments

The authors sincerely thank everyone who helped with this study. This study was funded by the Science and Technology Project of Xinjiang Production and Construction Corps (No. 2021AB030), the Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2020-PT330-003), the Innovative Development Project of Shihezi University (No. CXFZ2020005), and the nested case-control study of H-Type Hypertension in Kazakhs in Xinjiang (No. RCZK2018C01).

References

[1] H. Pang, B. Han, Q. Fu, L. Hao, and Z. Zong, “Association between homocysteine and conventional predisposing factors on risk of stroke in patients with hypertension,” Scientific Reports, vol. 8, no. 1, p. 3900, 2018.
[2] Y. Li, X. Qin, L. Luo et al., “Folic acid therapy reduces the risk of mortality associated with heavy proteinuria among hypertensive patients,” Journal of Hypertension, vol. 35, no. 6, pp. 1302–1309, 2017.
[3] L. Dong, L. Chen, H. Li et al., “Chinese guidelines for the management of hypertension,” Chinese Journal of Cardiovascular, vol. 44, pp. 24–56, 2019.
[4] S. Komal, J. J. Yin, S. H. Wang et al., “MicroRNAs: emerging biomarkers for atrial fibrillation,” Journal of Cardiology, vol. 74, no. 6, pp. 475–482, 2019.
[5] W. Zhang, Z. Tao, F. Xu et al., “An overview of miRNAs involved in PASMC phenotypic switching in pulmonary hypertension,” BioMed Research International, vol. 2021, Article ID 5765029, 18 pages, 2021.
[6] A. A. Khan, V. Gupta, and N. R. Mahapatra, “Key regulatory miRNAs in lipid homeostasis: implications for cardiometabolic diseases and development of novel
therapeutics,” Drug Discovery Today, vol. 27, no. 8, pp. 2170–2180, 2022.
[7] W. T. Gerthoffer, “Mechanisms of vascular smooth muscle cell migration,” Circulation Research, vol. 100, no. 5, pp. 607–621, 2007.
[8] F. Z. Marques, A. E. Campain, M. Tomaszewski et al., “Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for MicroRNAs,” Hypertension, vol. 58, no. 6, pp. 1093–1098, 2011.
[9] Y. Luo, H. Y. Dong, B. Zhang et al., “miR-29a-3p attenuates hypoxic pulmonary hypertension by inhibiting pulmonary adventitial fibroblast activation,” Hypertension, vol. 65, no. 2, pp. 414–420, 2015.
[10] Y. Liu, G. Liu, H. Zhang, and J. Wang, “MiRNA-199a-5p correlates with blood pressure in premature Smad3,” Biochemical and Biophysical Research Communications, vol. 473, no. 4, pp. 859–866, 2016.
[11] S. M. Lynch, M. Ward, H. McNulty et al., “Serum levels of miR-199a-5p correlates with blood pressure in premature cardiovascular disease patients homozygous for the MTHFR 677C>T polymorphism,” Genomics, vol. 112, no. 1, pp. 669–676, 2020.
[12] P. Paul, A. Chakraborty, D. Sarkar et al., “Interplay between miRNAs and human diseases,” Journal of Cellular Physiology, vol. 233, no. 3, pp. 2007–2018, 2018.
[13] Z. Tang, L. Xiao, J. Q. Wang, and T. Zhang, “Analysis of metabolism-related indicators and MTHFR gene polymorphism in patients with H-type hypertension,” Minerva Medica, vol. 108, no. 2, pp. 103–107, 2017.
[14] H. McNulty, J. J. Strain, C. F. Hughes, and M. Ward, “Riboflavin, MTHFR genotype and blood pressure: a personalized approach to prevention and treatment of hypertension,” Molecular Aspects of Medicine, vol. 53, pp. 2–9, 2017.
[15] S. Pushpakumar, S. Kundu, G. Weber, and U. Sen, “Exogenous hydrogen sulfide and miR-21 antagonism attenuates macrophage-mediated inflammation in ischemia reperfusion injury of the aged kidney,” Geroscience, vol. 43, no. 3, pp. 1349–1367, 2021.
[16] M. Lucock, Z. Yates, C. Martin et al., “Hydrogen sulphide-related thiol metabolism and nutrigenetics in relation to hypertension in an elderly population,” Genes and Nutrition, vol. 8, no. 2, pp. 221–229, 2013.
[17] P. Ventura, E. Corradini, E. Di Pierro et al., “Hyperhomocysteinemia in patients with acute porphyrias: a potentially dangerous metabolic crossroad?” European Journal of Internal Medicine, vol. 79, pp. 101–107, 2020.
[18] M. E. Widlansky, D. M. Jensen, J. Wang et al., “miR29 contributes to normal endothelial function and can restore it in cardiometabolic disorders,” EMBO Molecular Medicine, vol. 10, no. 3, Article e8046, 2018.
[19] A. Kalani, P. K. Kamat, A. Familtseva et al., “Role of MicroRNA29b in blood-brain barrier dysfunction during hyperhomocysteinemia: an epigenetic mechanism,” Journal of Cerebral Blood Flow and Metabolism, vol. 34, no. 7, pp. 1212–1222, 2014.
[20] J. Lin, R. M. Zeng, R. N. Li, and W. Cao, “Aberrant DNA methylation of the P16, MGMT, and hMLH1 genes in combination with the methylenetetrahydrofolate reductase C677T genetic polymorphism and folate intake in gastric cancer,” Genetics and Molecular Research, vol. 13, no. 1, pp. 2060–2068, 2014.
[21] N. Gu, L. You, C. Shi et al., “Expression of miR-199a-3p in human adipocytes is regulated by free fatty acids and adipokines,” Molecular Medicine Reports, vol. 14, no. 2, pp. 1180–1186, 2016.
[22] Y. Zhang, K. J. Fan, Q. Sun et al., “Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway,” Nucleic Acids Research, vol. 40, no. 18, pp. 9286–9297, 2012.
[23] I. Hromadnikova, K. Kotelova, L. Hympanova, and L. Krofa, “Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease-related miRNAs and associated microRNAs in maternal whole peripheral blood,” Thrombosis Research, vol. 137, pp. 126–140, 2016.
[24] L. Wan, Y. Li, Z. Zhang, Z. Sun, Y. He, and R. Li, “Methylenetetrahydrofolate reductase and psychiatric diseases,” Translational Psychiatry, vol. 8, no. 1, p. 242, 2018.
[25] Q. Yao, Y. Chen, and Z. Zhou, “The roles of microRNAs in epigenetic regulation,” Current Opinion in Chemical Biology, vol. 51, pp. 11–19, 2017.
[26] J. L. Guéant, R. M. Guéant-Rodriguez, V. J. Kosgei, and D. Coelho, “Causes and consequences of impaired methionine synthase activity in acquired and inherited disorders of vitamin B (12) metabolism,” Critical Reviews in Biochemistry and Molecular Biology, vol. 57, pp. 1–23, 2021.
[27] G. C. Román, O. Mancera-Páez, and C. Bernal, “Epigenetic factors in late-onset alzheimer’s disease: MTHFR and CTH gene polymorphisms, metabolic transsulfuration and methylation pathways, and B vitamins,” International Journal of Molecular Sciences, vol. 20, no. 2, p. E319, 2019.
[28] D. Tong, J. Zhang, X. Wang et al., “MiR-22, regulated by MeCP2, suppresses gastric cancer cell proliferation by inducing a deficiency in endogenous S-adenosylmethionine,” Oncogenesis, vol. 9, no. 11, p. 99, 2020.
[29] X. Cui, Y. Guo, Q. Wang, and X. Li, “MiR1993p-Dnmt3aSTAT3 signalling pathway in ovalbumin induced allergic rhinitis,” Experimental Physiology, vol. 104, no. 8, pp. 1286–1295, 2019.
[30] L. Yang, L. Rau, and M. A. Goodell, “DNMT3A in haematological malignancies,” Nature Reviews Cancer, vol. 15, no. 3, pp. 152–165, 2015.
[31] E. Grossi, A. Stocco, P. Tannorella, L. Migliore, and F. Coppede, “Artificial neural networks link one-carbon metabolism to gene-promoter methylation in alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 53, no. 4, pp. 1517–1522, 2016.
[32] L. Keat Wei, H. Sutherland, A. Au et al., “A potential epigenetic maker mediating serum folate and vitamin B12 levels contributes to the risk of ischemic stroke,” BioMed Research International, vol. 2015, Article ID 167976, 4 pages, 2015.
[33] R. M. Kok, D. E. C. Smith, R. Barto et al., “Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 7, pp. 903–911, 2007.
[34] G. H. Kim, J. J. Ryan, G. Marsboom, and S. L. Archer, “Epigenetic mechanisms of pulmonary hypertension,” Pulmonary Circulation, vol. 1, no. 3, pp. 347–356, 2011.
[35] J. Wang, L. Gong, Y. Tan, R. Hui, and Y. Wang, “Hypertensive epigenetics: from DNA methylation to microRNAs,” Journal of Human Hypertension, vol. 29, no. 10, pp. 575–582, 2015.
[36] T. Hassan, T. P. Carroll, P. G. Buckley et al., “miR-199a-5p silencing regulates the unfolded protein response in chronic obstructive pulmonary disease and α1-antitrypsin deficiency,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 3, pp. 263–273, 2014.
[37] E. L. Beckett, C. Martin, J. H. Choi et al., “Folate status, folate-related genes and serum miR-21 expression: implications for miR-21 as a biomarker,” *BBA Clinical*, vol. 4, pp. 45–51, 2015.

[38] D. Ji, C. Luo, J. Liu et al., “Insufficient S-sulphydrylation of methylenetetrahydrofolate reductase contributes to the progress of hyperhomocysteinemia,” *Antioxidants and Redox Signaling*, vol. 36, no. 1-3, pp. 1–14, 2022.

[39] Z. Zhang, Y. Cao, Y. Zhai et al., “MicroRNA-29b regulates DNA methylation by targeting Dnmt3a/3b and Tet1/2/3 in porcine early embryo development,” *Development Growth and Differentiation*, vol. 60, no. 4, pp. 197–204, 2018.

[40] P. L. Palmbos, L. Wang, H. Yang et al., “ATDC/TRIM29 drives invasive bladder cancer formation through miRNA-mediated and epigenetic mechanisms,” *Cancer Research*, vol. 75, no. 23, pp. 5155–5166, 2015.

[41] S. Guo, H. Pang, H. Guo et al., “Ethnic differences in the prevalence of high homocysteine levels among low-income rural Kazakh and Uyghur adults in far western China and its implications for preventive public Health,” *International Journal of Environmental Research and Public Health*, vol. 12, no. 5, pp. 5373–5385, 2015.